Universite Joseph Fourier Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2005
NCT00529711
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aina Chalabaev | Director, INSERM-E0221-Bioenergetique Fondamentale et appliquee, Universite Joseph Fourier, France | Université Joseph Fourier

Active Ingredients

Drugs in Phase 3 Trials (2)

lactic acid (1 trial)

ringer's lactate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiac Output, Low (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2